A5011200161- Pulmonary Hypertension Research and Treatments
- Cardiovascular Function and Risk Factors
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cardiovascular Issues in Pregnancy
- Vascular Anomalies and Treatments
- Heart Failure Treatment and Management
- Cardiac Imaging and Diagnostics
- Atomic and Subatomic Physics Research
- Advanced MRI Techniques and Applications
- Congenital Heart Disease Studies
- Medical Imaging and Pathology Studies
- Liver Disease and Transplantation
- Systemic Sclerosis and Related Diseases
- Cardiovascular Disease and Adiposity
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cardiac Valve Diseases and Treatments
- Venous Thromboembolism Diagnosis and Management
- Ultrasound in Clinical Applications
- MicroRNA in disease regulation
- Heart Rate Variability and Autonomic Control
- Nitric Oxide and Endothelin Effects
- Cardiac Arrhythmias and Treatments
- Liver Disease Diagnosis and Treatment
- Circular RNAs in diseases
- Atrial Fibrillation Management and Outcomes
Sheffield Teaching Hospitals NHS Foundation Trust
2016-2025
University of Sheffield
2016-2025
Royal Hallamshire Hospital
2015-2024
Insigneo
2015-2024
Pulmonary Associates
2005-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2024
National Institute for Health Research
2011-2024
Hospital Clínic de Barcelona
2024
MultiMedica
2024
Johnson & Johnson (Switzerland)
2021-2023
Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics exercise capacity in patients with hypertension.
2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations focusing on clinical management https://bit.ly/3QtUvb4
Rationale: Pulmonary arterial hypertension in association with connective tissue disease (CTD-PAH) has historically had a poor prognosis, 1-year survival rate among patients systemic sclerosis–associated pulmonary (SSc-PAH) of 45%. However, more therapies have become available.Objectives: To investigate the and characteristics all diagnosed CTD-PAH U.K. service.Methods: National registry incident cases consecutively between January 2001 June 2006.Measurements Main Results: Patients (429; 73%...
Incident pulmonary arterial hypertension was underrepresented in most registries and may have a different disease profile to prevalent disease.To determine the characteristics outcome of purely incident, treatment-naive cohort idiopathic, heritable, anorexigen-associated changes presentations survival over past decade United Kingdom Ireland.All consecutive newly diagnosed patients from 2001 2009 were identified prospectively.A total 482 (93% 5% 2% hypertension) diagnosed, giving rise an...
The management of chronic thromboembolic pulmonary hypertension (CTEPH) has changed over recent years with the growth endarterectomy surgery and availability disease-modifying therapies.To investigate prognosis CTEPH in a national setting during years.All incident cases diagnosed one five centers United Kingdom between January 2001 June 2006 were identified prospectively. Information regarding baseline characteristics, treatment, follow-up was subsequently collected from hospital records.A...
Background— Chronic thromboembolic pulmonary hypertension results from incomplete resolution of emboli. Pulmonary endarterectomy (PEA) is potentially curative, but residual following surgery common and its impact on long-term outcome poorly understood. We wanted to identify factors correlated with poor after specifically define clinically relevant post-PEA. Methods Results— Eight hundred eighty consecutive patients (mean age, 57 years) underwent PEA for chronic hypertension. Patients...
Pulmonary arterial hypertension (PAH) is a rare disorder with poor prognosis. Deleterious variation within components of the transforming growth factor-β pathway, particularly bone morphogenetic protein type 2 receptor (BMPR2), underlies most heritable forms PAH. To identify missing heritability we perform whole-genome sequencing in 1038 PAH index cases and 6385 PAH-negative control subjects. Case-control analyses reveal significant overrepresentation variants ATP13A3, AQP1 SOX17, provide...
After the approval of bosentan for treatment pulmonary arterial hypertension (PAH), European authorities required introduction a post-marketing surveillance system (PMS) to obtain further data on its safety profile. A novel, prospective, internet-based PMS was designed, which solicited reports elevated aminotransferases, medical reasons discontinuation and other serious adverse events requiring hospitalisation. Data captured included demographics, PAH aetiology, baseline functional status...
Pregnancy outcomes in patients with pulmonary hypertension remain poor despite advanced therapies. Although consensus guidelines recommend against pregnancy hypertension, it may nonetheless occasionally occur. This guideline document sought to discuss the state of knowledge effects on vascular disease and define usual practice avoidance management. is based systematic review peer-reviewed, published literature identified MEDLINE. The strength was graded, when inadequate support high-level...
Metabolic modulation with dichloroacetate improves hemodynamics in genetically susceptible patients idiopathic pulmonary arterial hypertension.
The phenotype and outcome of severe pulmonary hypertension in chronic obstructive disease (COPD) is described small numbers, predictors survival are unknown. Data was retrieved for 101 consecutive, treatment-naïve cases COPD. Mean ± SD follow-up 2.3 1.9 years. 59 patients with COPD hypertension, defined by catheter mean artery pressure ≥40 mmHg, had significantly lower carbon monoxide diffusion, less airflow obstruction but not different emphysema scores on computed tomography compared to 42...
Background: Pulmonary arterial hypertension (PAH) is a heterogeneous disorder with high mortality. Methods: We conducted comprehensive study of plasma metabolites using ultraperformance liquid chromatography mass spectrometry to identify patients at risk early death, who respond well treatment, and provide novel molecular insights into disease pathogenesis. Results: Fifty-three circulating distinguished well-phenotyped idiopathic or heritable PAH (n=365) from healthy control subjects (n=121)...
BackgroundAmong patients meeting diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH), there is an emerging lung phenotype characterised by a low diffusion capacity carbon monoxide (DLCO) and smoking history. The present study aimed at detailed characterisation of these patients.MethodsWe analysed data from two European registries, COMPERA (launched in 2007) ASPIRE (from 2001 onwards), to identify diagnosed with IPAH defined DLCO less than 45% predicted We compared...
Pulmonary endarterectomy (PEA), pulmonary arterial hypertension (PAH) therapy and balloon angioplasty (BPA) are currently accepted therapies for chronic thromboembolic (CTEPH). This international CTEPH Registry identifies clinical characteristics of patients, diagnostic algorithms treatment decisions in a global context.1010 newly diagnosed consecutive patients were included the registry between February 2015 September 2016. Diagnosis was confirmed by right heart catheterisation,...
Several prognostic variables have previously been identified in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Specific medical conditions also associated the development and prognosis of CTEPH. Using a national registry, current authors assessed value larger number attempted to validate clinical importance aetiological factors. Baseline information for all 469 CTEPH diagnosed UK service between January 2001 June 2006 was collected from hospital records. Although...
MicroRNAs (miRNAs or miRs) are implicated in the pathogenesis of various cardiovascular diseases, including pulmonary arterial hypertension (PAH).We sought to measure changes plasma levels miRNAs patients with PAH and relate them severity disease.A microarray screen was performed on total RNA from eight healthy control subjects. Quantitative polymerase chain reaction confirmed reduced miR-150 concentrations then used (1) two separate cohorts PAH, London (n = 145) Sheffield 30), respectively;...
The aim of this study was to develop a measure the impact pulmonary hypertension (PH) on health-related quality life (HRQoL) as there is need for short, validated instrument that can be used in routine clinical practice. Interviews were conducted with 30 PH patients derive 32 statements, which presented semantic differential six-point scale (0–5), contrasting adjectives at each end. This item list completed by attending clinics across UK and Ireland. Rasch analysis applied identify items...
Objectives of this European Respiratory Society task force were to summarise current studies, develop strategies for future research and increase availability awareness exercise training pulmonary hypertension (PH) patients. An evidence-based approach with clinical expertise the members, based on both literature search face-to-face meetings was conducted. The statement summarises knowledge open questions regarding effects in PH, modalities, implementation pathophysiological mechanisms. In...